Akorn Pharmaceuticals, originally founded in 1948 as Taylor Pharmacy, is a specialty generic pharmaceutical company which develops, manufactures, and markets specialized generic and branded pharmaceuticals, including over-the-counter (OTC) drugs.
The company operates in two basic segments, Prescription Pharmaceuticals and Consumer Health. The Prescription Pharmaceuticals segment offers generic and branded prescription drugs in various dosage forms. The Consumer Health sector manufactures and markets OTC products for the treatment of dry eyes under the TheraTears brand, as well as other OTC consumer health products, including Mag-Ox, a magnesium supplement; and the Diabetic Tussin line of cough and cold products. In April of 2017, the company was acquired by Fresenius for $4.3 billion.
Akorn is listed as #19 on the Fortune 100 list of Fastest Growing Companies in America. In 2016, the company had annual revenue of $4.4 billion and a three year growth rate of 93 percent. The company is publicly traded on the NASDAQ under the ticker symbol: AKRX